secwatch.observer — SEC 8-K summary
======================================

Issuer:     Gain Therapeutics, Inc. (GANX)
CIK:        0001819411
Form:       8-K
Filed at:   2025-03-27T23:59:59+00:00
Accession:  0001558370-25-003807
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Gain Therapeutics reports FY2024 net loss $20.4M; Phase 1b dosing initiated for GT-02287
--------------------------------------------------------------------------------

- Net loss of $20.4M ($0.89 EPS) vs $22.3M ($1.71 EPS) in FY2023; revenue not reported.
- Cash and securities $10.4M at Dec 31, 2024, down from $16.8M a year earlier.
- First patient dosed in Phase 1b trial of GT-02287 for Parkinson's disease; first analysis expected Q2 2025.
- Gene Mack appointed President and CEO effective Jan 6, 2025; pre-IND engagement with FDA started.
- R&D expenses fell to $10.8M and G&A to $9.6M vs $11.5M and $10.8M in FY2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1819411/000155837025003807/0001558370-25-003807-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1819411/000155837025003807/ganx-20250327x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-25-003807

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer